Autolus FIRST LOOK: 3Q24 update focusses on Aucatzyl's launch in r/r adult ALL
Yesterday before US market opens, Autolus reported 3Q24 results with a cash position of $657.1m (YE23: $239.9m), sufficient to drive Aucatzyl's (obe-cel, CD19 CAR-T) launch in r/r adult ALL, and advance the company's pipeline towards pivotal autoimmune data (KBCSe 2028). The focus of the 3Q24 update was Aucatzyl's upcoming launch, and we expect the large safety differentiation vs. Tecartus to be a key factor for adoption. In parallel, we look forward to initial autoimmune data in 1Q25, which has the potential to expand Aucatzyl's commercial opportunity and bring upside to the stock. We reiterate our $11 TP and Buy rating.